A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo

Pharmaceutical Research

Volumn 26, Issue 4, 2009, Pages 926-935

  Han, Min ^a   He, Cai Xia ^a   Fang, Qiu Li ^a   Yang, Xiao Chun ^a   Diao, Yuan Yuan ^a   Xu, Dong Hang ^b   He, Qiao Jun ^a   Hu, Yong Zhou ^a   Liang, Wen Quan ^a   Yang, Bo ^a   Gao, Jian Qing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

10 Methoxy 9 nitrocamptothecin (MONCPT); Anti tumor; Fluorescence; Nanoemulsion; Nile red

Indexed keywords

10 METHOXY 9 NITROCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CREMOPHOR; CYCLOPHOSPHAMIDE; LACTONE; SULFORHODAMINE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROFLUIDIC ANALYSIS; MOUSE; NANOEMULSION; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; EMULSIFYING AGENTS; EMULSIONS; FLUORESCENT DYES; GLYCEROL; HEMOLYSIS; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KINETICS; MALE; MICE; MICROSCOPY, FLUORESCENCE; NANOSTRUCTURES; NEOPLASMS; OXAZINES; PARTICLE SIZE; RABBITS; SOLUBILITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 61449224487     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9795-9     Document Type: Article

References (33)

1. C. H. Takimoto J. Wright S. G. Arbuck 1998 Clinical applications of the camptothecins Biochim. Biophys. Acta 1400 107 119
2. O. Lavergne D. C. Bigg 1998 The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan Bull. Cancer 12 51 58
3. U. Vanhoefer W. Achterrath S. Cao S. Seeber Y. M. Rustum 2001 Irinotecan in the treatment of colorectal cancer: clinical overview J. Clin. Oncol. 19 1501 1518
4. Z. S. Cao K. Armstrong M. Shaw E. Petry N. Harris 1998 Nitration of camptothecin with various inorganic nitrate salts in concentrated sulfuric acid: a new preparation of anticancer drug 9-nitrocamptothecin Synthesis 12 1724 1730
5. M. C. Wani A. W. Nicholas M. E. Wall 1986 Plant antitumor agents.23. Synthesis and antileukemic activity of camptothecin analogues J. Med. Chem. 29 2858 2863
6. M. Gao K. D. Miller G. W. Sledgeb Q. H. Zheng 2005 Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers Bioorg. Med. Chem. Lett. 15 3865 3869
7. X. C. Yang P. H. Luo B. Yang Q. J. He 2006 Antiangiogenesis response of endothelial cells to the antitumour drug 10-methoxy-9-nitrocamptothecin Pharmacol. Res. 54 334 340
8. P. H. Luo Q. J. He X. G. He Y. Z. Hu W. Lu Y. Y. Cheng B. Yang 2006 Potent antitumor activity of 10-methoxy-9-nitrocamptothecin Mol. Cancer. Ther. 54 962 968
9. C. J. Thomas N. J. Rahier S. M. Hecht 2004 Camptothecin: current perspectives Bioorg. Med. Chem. 12 1585 1604
10. J. J. Zhou J. Liu B. Xu 2001 Relationship between lactone ring forms of HCPT and their antitumor activities Acta. Pharmacol. Sin. 22 827 830
11. R. P. Hertzberg M. J. Caranfa K. G. Holden D. R. Jakas G. Gallagher M. R. Mattern S. M. Mong J. O. Bartus R. K. Johnson W. D. Kingsbury 1989 Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity J. Med. Chem. 32 715 720
12. S. Kawakami F. Yamashita M. Hasida 2000 Disposition characteristics of emulsions and incorporated drugs after systemic or local injection Adv. Drug Deliv. Rev. 45 77 88
13. P. P. Constantinides K. J. Lambert A. K. Tustian B. Schneider S. Lalji W. Ma B. Wentzel D. Kessler D. Worah S. C. Quay 2000 Formulation development and antitumor activity of filter-sterilizable emulsion of paclitaxel Pharm. Res. 17 175 182
14. J. Rossi S. Giasson M. N. Khalid P. Delmas C. Allen J. C. Leroux 2007 Long-circulation poly (ethylene glycol)-coated emulsions to target solid tumors Eur. J. Pharm. Biopharm. 67 329 338
15. K. Zurowska-Pryczkowska M. Sznitowska S. Janicki 1999 Studies on the effect of pilocarplne incorporation into a submicron emulsion on the stability of the drug and the vehicle Eur. J. Pharm. Biopharm. 47 255 260
16. M. J. Lawrence G. D. Rees 2000 Microemulsion-based media as novel drug delivery systems Adv. Drug Deliv. Rev. 45 89 121
17. O. Sonneville-Aubrun J. T. Simonnet F. l'Alloret 2004 Nanoemulsions: a new vehicle for skincare products Adv. Colloid Interface Sci. 108-109 145 149
18. L. A. Pires, R. Hegg, C. J. Valduga, S. R. Graziani, D. G. Rodrigues, and R. C. Maranhao. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother Pharmacol., in press (2008) http://www.springerlink.com/content/ t1452120506h7327/.
19. D. Attivi 2005 Formulation of insulin-loaded polymeric nanoparticles using response surface methodology Drug DeV. Ind. Pharm. 31 179 189
20. L. Copolovici U. Niinemets 2007 Salting-in and salting-out effects of ionic and neutral osmotica on limonene and linalool Henry's law constants and octanol/water partition coefficients Chemosphere 69 621 629
21. M. Y. Levy S. Benita 1990 Drug release from submicronized o/w emulsion: new in vitro kinetic evaluation model Int. J. Pharm. 66 29 37
22. M. B. Moshe S. Magdassi Y. Cohen L. Avram 2004 Structure of microemulsions with Gemini surfactant studied by solvatochromic probe and diffusion NMR J. Colloid Interface Sci. 276 221 226
23. P. Skehan D. Scudiero R. Storeng A. Monks J. McMahon D. Vistica J. T. Warren H. Bokesch S. Kenney M. R. Boyd 1990 New colorimetric cytotoxicity assay for anticancer-drug screening J. Nat. Cancer Inst. 82 1107 1112
24. S. S. Rane B. D. Anderson 2008 What determines drug solubility in lipid vehicles: is it predictable Adv. Drug Del. Rev. 60 638 656
25. C. Malcolmson C. Satra S. Kantaria A. Sidhu M. J. Lawrence 1998 Effect of oil on the level of solubilization of testosterone propionate into nonionic oil-in-water microemulsions J. Pharm. Sci. 87 109 116
26. H. Kunieda N. Masuda K. Tsubone 2000 Comparison between phase behavior of anionic dimeric (Gemini-Type) and monomeric surfactants in water and water-oil Langmuir. 16 6438 6444
27. F. Liu D. Liu 1995 Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs Pharm. Res. 12 1060 1064
28. D. F. Zhong K. Li J. H. Xu Y. Du Y. F. Zhang 2003 Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats Acta Pharmacol. Sin. 24 256 262
29. P. K. Ghosh R. S. R. Murthy 2006 Microemulsions: a potential drug delivery system Curr. Drug Deliv. 3 167 180
30. J. B. Tagne S. Kakumanu D. Ortiz T. Shea R. J. Nicolosi 2008 A nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line Mol. Pharm. 5 280 286
31. T. Masuda H. Akita T. Nishio K. Niikura K. Kogure K. Ijiro H. Harashima 2008 Development of lipid particles targeted via sugar-lipid conjugates as novel nuclear gene delivery system Biomaterials 29 709 723
32. W. Junping K. Takayama T. Nagai Y. Maitani 2003 Pharmacokinetics and antitumor effects of vincristine carried by microemulsions composed of PEG-lipid, oleic acid, vitamin E and cholesterol Int. J. Pharm. 251 13 21
33. B. A. Teicher 2000 Molecular targets and cancer therapeutics: discovery, development and clinical validation Drug Resist Updat. 3 67 73